Cargando…

Potential Risks of Pharmacy Compounding

Pharmacy compounding involves the preparation of customized medications that are not commercially available for individual patients with specialized medical needs. Traditional pharmacy compounding is appropriate when done on a small scale by pharmacists who prepare the medication based on an individ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gudeman, Jennifer, Jozwiakowski, Michael, Chollet, John, Randell, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing AG 2013
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627035/ https://www.ncbi.nlm.nih.gov/pubmed/23526368 http://dx.doi.org/10.1007/s40268-013-0005-9

Ejemplares similares

Pharmacy Compounding Primer for Physicians: Prescriber Beware
por: Sellers, Sarah, et al.
Publicado: (2012)

Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
por: van der Pol, Karel H., et al.
Publicado: (2023)

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
por: Urban, Philip, et al.
Publicado: (2019)

eClinic: increasing use of telehealth as a risk reduction strategy during the covid-19 pandemic
por: Kemp, Michael T, et al.
Publicado: (2020)

Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values?
por: Peasgood, Tessa, et al.
Publicado: (2015)

Therapeutic Potential of Transdermal Glyceryl Trinitrate in the Management of Acute Stroke
por: Appleton, Jason P., et al.
Publicado: (2016)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Medical Information Delivering Improved Customer Experience: A Guide
por: Guillot, Pete, et al.
Publicado: (2023)

Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
por: Pavelka, Karel, et al.
Publicado: (2016)

Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential
por: Cecil, Charlotte A. M., et al.
Publicado: (2022)

The Underrated Risks of Tamoxifen Drug Interactions
por: Hansten, Philip D.
Publicado: (2018)

Time to Differentiate Postactivation “Potentiation” from “Performance Enhancement” in the Strength and Conditioning Community
por: Prieske, Olaf, et al.
Publicado: (2020)

Deceleration Training in Team Sports: Another Potential ‘Vaccine’ for Sports-Related Injury?
por: McBurnie, Alistair J., et al.
Publicado: (2021)

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
por: Bianconi, Vanessa, et al.
Publicado: (2020)

The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19
por: Panera, Nadia, et al.
Publicado: (2020)

Frailty and Potentially Inappropriate Prescribing in Older People with Polypharmacy: A Bi-Directional Relationship?
por: Randles, Mary A., et al.
Publicado: (2022)

Drug Exposure and the Risk of Microscopic Colitis: A Critical Update
por: Lucendo, Alfredo J.
Publicado: (2017)

Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
por: Napoli, Claudio, et al.
Publicado: (2020)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis
por: Bruyère, Olivier, et al.
Publicado: (2015)

‘Longing’ for the Next Generation of Liquid Biopsy: The Diagnostic Potential of Long Cell-Free DNA in Oncology and Prenatal Testing
por: Yu, Stephanie C. Y., et al.
Publicado: (2023)

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
por: Bello, Alfonso E., et al.
Publicado: (2014)

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty
por: Arden, Nigel, et al.
Publicado: (2015)

Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
por: Caro, J. Jaime, et al.
Publicado: (2018)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
por: Charpiat, Bruno, et al.
Publicado: (2020)

Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?
por: Navarese, Eliano Pio, et al.
Publicado: (2013)

Advancing the Field of Pharmaceutical Risk Minimization Through Application of Implementation Science Best Practices
por: Smith, Meredith Y., et al.
Publicado: (2014)

A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials
por: Patera, Andriani C., et al.
Publicado: (2023)

The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data
por: Buoli, Massimiliano, et al.
Publicado: (2017)

Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?
por: Vass, Caroline M., et al.
Publicado: (2017)

Will the EU Clinical Trials Regulation Support the Innovative Industry in Bringing New Medicines Faster to Patients?
por: Atzor, Sabine, et al.
Publicado: (2013)

Controversial role of plant sterol esters in the management of hypercholesterolaemia
por: Weingärtner, Oliver, et al.
Publicado: (2009)

Embracing the Evolution of Pharmacy Practice by Empowering Pharmacy Technicians
por: Burke, Ryan
Publicado: (2020)

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
por: Zheng, Crystal, et al.
Publicado: (2020)

NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View
por: Angoulvant, Denis, et al.
Publicado: (2021)

Mass casualty events: what to do as the dust settles?
por: Russo, Rachel M, et al.
Publicado: (2018)

Specialization in acute care surgery in low-income and middle-income countries
por: Yi, Sojung, et al.
Publicado: (2017)

Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors: Recommendations for Patient Selection, Risk Assessment, and Molecular Response Monitoring
por: Rutkowski, Piotr, et al.
Publicado: (2013)

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
por: Annemans, Lieven, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_06rh5n6i0b7emgjrandjl59k6f